Literature DB >> 9651632

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection.

F Averhoff1, F Mahoney, P Coleman, G Schatz, E Hurwitz, H Margolis.   

Abstract

OBJECTIVE: To assess risk factors for decreased immunogenicity among adults vaccinated with hepatitis B vaccine and to determine the importance of differences in immunogenicity between vaccines among health care workers (HCWs).
DESIGN: Randomized clinical trial and decision analysis. PARTICIPANTS: HCSw. MAIN OUTCOME MEASURES: Development of seroprotective levels of antibody to hepatitis B surface antigen (anti-HBs) and the number of expected chronic hepatitis B virus (HBV) infections associated with lack of protection.
RESULTS: Overall, 88% of HCWs developed seroprotection. Risk factors associated with failure to develop seroprotection included increasing age, obesity, smoking and male gender (P < .05). Presence of a chronic disease was associated with lack of seroprotection only among persons > or = 40 years of age (P < .05). The two vaccines studied differed in their overall seroprotection rates (90% vs. 86%; P < .05), however, this difference was restricted to persons > or = 40 years of age (87% vs. 81%; P < .01). Among HCWs > or = 40 years of age, the decision analysis found 44 (0.34/100,000 person-years) excess chronic HBV infections over the working life of the cohort associated with use of the less immunogenic vaccine compared to the other.
CONCLUSIONS: He patitis B vaccines are highly immunogenic, but have decreased immunogenicity associated with increasing age, obesity, smoking, and male gender; and among older adults, the presence of a chronic disease. One of the two available vaccines is more immunogenic among older adults; however, this finding has little clinical or public health importance. Hepatitis B vaccines should be administered to persons at occupational risk for HBV infection early in their career, preferably while they are still in their training.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9651632     DOI: 10.1016/s0749-3797(98)00003-8

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  64 in total

1.  Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users.

Authors:  Thanh Q Tran; Carolyn Z Grimes; Dejian Lai; Catherine L Troisi; Lu-Yu Hwang
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

2.  Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities.

Authors:  Rania A Tohme; Debo Awosika-Olumo; Carrie Nielsen; Salma Khuwaja; Jennifer Scott; Jian Xing; Jan Drobeniuc; Dale J Hu; Cynthia Turner; Toni Wafeeg; Umid Sharapov; Philip R Spradling
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

3.  Optimal vaccination program for healthy adults in China.

Authors:  Jun Yao; Yan Qiu; Yongdi Chen; Zhenggang Jiang; Lingzhi Shen; Huan Shan; Xuewei Dai; Qian Li; Ying Liu; Wen Ren; Jingjing Ren
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow.

Authors:  Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 5.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

6.  Sleep and antibody response to hepatitis B vaccination.

Authors:  Aric A Prather; Martica Hall; Jacqueline M Fury; Diana C Ross; Matthew F Muldoon; Sheldon Cohen; Anna L Marsland
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

7.  Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.

Authors:  Xue-Yan Liao; Zhen-Zuo Zhou; Fu-Bang Wei; Han-Ning Qin; Yuan Ling; Rong-Cheng Li; Yan-Ping Li; Yi Nong; Kui-Xia Sun; Jie Li; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

8.  Body height and immune efficacy: testing body stature as a signal of biological quality.

Authors:  Bogusław Pawłowski; Judyta Nowak; Barbara Borkowska; Daria Augustyniak; Zuzanna Drulis-Kawa
Journal:  Proc Biol Sci       Date:  2017-07-26       Impact factor: 5.349

9.  Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis.

Authors:  Erik Seth Kramer; Charlotte Hofmann; Paula G Smith; Mitchell L Shiffman; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

10.  Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children.

Authors:  Salvatore Leonardi; Andrea Domenico Praticò; Elena Lionetti; Massimo Spina; Giovanna Vitaliti; Mario La Rosa
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.